Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disord ...

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=161654&from=4CLASS PERIOD: August 10, 2023 to June ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3]

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. following a class action lawsuit related to the company's performance during a specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit was filed for investors who purchased or acquired Altimmune securities between August 10, 2023, and June 25, 2025 [1][2]. - The lawsuit alleges that Altimmune's IMPACT study failed to achieve statistical significance in its primary endpoint of fibrosis reduction, which was attributed to a higher-than-expected placebo response [3]. - Following the announcement of the study results on June 26, 2025, Altimmune's stock price dropped 53%, from $7.71 per share to $3.61 per share, resulting in significant losses for investors [4]. Group 2: Company Background - Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland [2]. - Berger Montague has a long history in securities class action litigation, having represented individual and institutional investors for over five decades [5].

Core Viewpoint - Altimmune faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [2][3]. Group 1: Trial Results - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, revealing a failure to achieve statistical significance in fibrosis reduction [2]. - The trial showed a positive trend in fibrosis improvement; however, this was overshadowed by a higher-than-expected placebo response [2]. Group 2: Stock Market Reaction - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - A court-appointed lead plaintiff has been established, representing the investor with the largest financial interest in the class action lawsuit against Altimmune [4]. - Members of the putative class have the option to serve as lead plaintiff or remain absent, with their ability to share in any recovery unaffected by this decision [4]. Group 4: Whistleblower Information - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Altimmune's conduct, including whistleblowers and former employees, to come forward [5].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2] - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The allegations state that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price dropped from $7.71 per share to $3.61 per share, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs are required [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, which led to a significant drop in its stock price [3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in the development of treatments for liver diseases, specifically focusing on MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [3]. - The company reported topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which did not meet the expected statistical significance for its primary endpoint related to fibrosis reduction [3]. Group 2: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to register for participation in the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025 [4].

Financial Performance - Altimmune, Inc. reported a quarterly loss of 27 cents per share, which was better than market estimates of a loss of 32 cents per share [1] - The company's quarterly sales amounted to $5.000K [1] Clinical Development - Pemvidutide showed rapid and robust MASH effects, significant weight loss, and impressive safety and tolerability in the recent IMPACT Phase 2b trial [2] - The company is preparing for an End-of-Phase 2 Meeting with the FDA, which will facilitate the transition to Phase 3 development [2] - Full 48-week data is expected to be reported in the fourth quarter, with further updates anticipated as pemvidutide advances [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Altimmune shares increased by 5.7%, trading at $3.8250 [2] - B. Riley Securities analyst Mayank Mamtani maintained a Buy rating but lowered the price target from $20 to $18 [5] - UBS analyst Eliana Merle also maintained a Buy rating, reducing the price target from $26 to $24 [5] - HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating with a maintained price target of $12 [5]